Review



rabbit anti human jak2 antibody  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc rabbit anti human jak2 antibody
    Rabbit Anti Human Jak2 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1258 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+anti+human+jak2/Jak2+XP+Rabbit+mAb/pmc12857535-202-23-29
    Average 96 stars, based on 1258 article reviews
    rabbit anti human jak2 antibody - by Bioz Stars, 2026-09
    96/100 stars

    Images



    Similar Products

    90
    Thermo Fisher rabbit anti-human phospho-jak2 (y931) antibody
    ( A – D ) ISH was done with Mef2 intronic probes under each pharmacological inhibitor treatment; DMSO ( A ), 3i ( B ), Ruxolitinib ( C ) and 3i+Ruxolitinib ( D ). White arrows show the dotted signals of nascent Mef2 expression. White arrowhead shows lobe in ( B ). ( A ’– D ’) Magnification images of ( A – D ). ( A ”– D ”) Black and white images of the magenta channel of ( A’ – D’ ), respectively. ( E ) Proportion of B7.6* cells with Mef2 signals in nuclei ( y axis) under each pharmacological inhibitor treatment ( x axis). ( F ) Proportion of B7.6* lineage cells in embryos ( y axis) under each pharmacological inhibitor treatment. ( x axis). ( G – J ) Immunostaining with <t>anti-JAK2</t> antibody was done at the mid tailbud; 10 hpf ( G – H ’) and the late tailbud; 12 hpf ( I – J ’) stages. Image G is the same as the image on S5B. ( K ) Proportion of embryos with JAK2-positive B7.6* cells ( y axis). ( L , M ) ISH was done with Mef2 intronic probes under each pharmacological inhibitor treatment; DMSO ( L ) and Ruxolitinib ( M ) in 10 hpf embryos and quantified in ( N ). White arrows show the dotted signals of nascent Mef2 expression. ( N ) Proportion of Mef2 -positive B7.6* nuclei showing either 1 or 2 dots ( y axis) under each condition. ( O ) Proportion of cell numbers of B7.6* cells in embryos ( y axis) under each condition. Data information: ( E , F , K , N , O ) Error bars indicate standard error. P value was calculated by z-test. P > 0.05; N.S, 0.05> P > 0.01; *, 0.01> P ; **. Scale bars are 15 μm on ( A – D ), 20 μm on ( G , I ) and 5 μm on ( H , J , L , M ). .
    Rabbit Anti Human Phospho Jak2 (Y931) Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+anti+human+jak2/human+jak2+sirna+accell+smartpool+e+003146+00+0005/pmc11094015-212-1-6
    Average 90 stars, based on 1 article reviews
    rabbit anti-human phospho-jak2 (y931) antibody - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc rabbit anti human jak2 antibody
    ( A – D ) ISH was done with Mef2 intronic probes under each pharmacological inhibitor treatment; DMSO ( A ), 3i ( B ), Ruxolitinib ( C ) and 3i+Ruxolitinib ( D ). White arrows show the dotted signals of nascent Mef2 expression. White arrowhead shows lobe in ( B ). ( A ’– D ’) Magnification images of ( A – D ). ( A ”– D ”) Black and white images of the magenta channel of ( A’ – D’ ), respectively. ( E ) Proportion of B7.6* cells with Mef2 signals in nuclei ( y axis) under each pharmacological inhibitor treatment ( x axis). ( F ) Proportion of B7.6* lineage cells in embryos ( y axis) under each pharmacological inhibitor treatment. ( x axis). ( G – J ) Immunostaining with <t>anti-JAK2</t> antibody was done at the mid tailbud; 10 hpf ( G – H ’) and the late tailbud; 12 hpf ( I – J ’) stages. Image G is the same as the image on S5B. ( K ) Proportion of embryos with JAK2-positive B7.6* cells ( y axis). ( L , M ) ISH was done with Mef2 intronic probes under each pharmacological inhibitor treatment; DMSO ( L ) and Ruxolitinib ( M ) in 10 hpf embryos and quantified in ( N ). White arrows show the dotted signals of nascent Mef2 expression. ( N ) Proportion of Mef2 -positive B7.6* nuclei showing either 1 or 2 dots ( y axis) under each condition. ( O ) Proportion of cell numbers of B7.6* cells in embryos ( y axis) under each condition. Data information: ( E , F , K , N , O ) Error bars indicate standard error. P value was calculated by z-test. P > 0.05; N.S, 0.05> P > 0.01; *, 0.01> P ; **. Scale bars are 15 μm on ( A – D ), 20 μm on ( G , I ) and 5 μm on ( H , J , L , M ). .
    Rabbit Anti Human Jak2 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+anti+human+jak2/Jak2+XP+Rabbit+mAb/pmc12857535-202-23-29
    Average 96 stars, based on 1 article reviews
    rabbit anti human jak2 antibody - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc rabbit anti human phospho jak2 antibody
    ( A – D ) ISH was done with Mef2 intronic probes under each pharmacological inhibitor treatment; DMSO ( A ), 3i ( B ), Ruxolitinib ( C ) and 3i+Ruxolitinib ( D ). White arrows show the dotted signals of nascent Mef2 expression. White arrowhead shows lobe in ( B ). ( A ’– D ’) Magnification images of ( A – D ). ( A ”– D ”) Black and white images of the magenta channel of ( A’ – D’ ), respectively. ( E ) Proportion of B7.6* cells with Mef2 signals in nuclei ( y axis) under each pharmacological inhibitor treatment ( x axis). ( F ) Proportion of B7.6* lineage cells in embryos ( y axis) under each pharmacological inhibitor treatment. ( x axis). ( G – J ) Immunostaining with <t>anti-JAK2</t> antibody was done at the mid tailbud; 10 hpf ( G – H ’) and the late tailbud; 12 hpf ( I – J ’) stages. Image G is the same as the image on S5B. ( K ) Proportion of embryos with JAK2-positive B7.6* cells ( y axis). ( L , M ) ISH was done with Mef2 intronic probes under each pharmacological inhibitor treatment; DMSO ( L ) and Ruxolitinib ( M ) in 10 hpf embryos and quantified in ( N ). White arrows show the dotted signals of nascent Mef2 expression. ( N ) Proportion of Mef2 -positive B7.6* nuclei showing either 1 or 2 dots ( y axis) under each condition. ( O ) Proportion of cell numbers of B7.6* cells in embryos ( y axis) under each condition. Data information: ( E , F , K , N , O ) Error bars indicate standard error. P value was calculated by z-test. P > 0.05; N.S, 0.05> P > 0.01; *, 0.01> P ; **. Scale bars are 15 μm on ( A – D ), 20 μm on ( G , I ) and 5 μm on ( H , J , L , M ). .
    Rabbit Anti Human Phospho Jak2 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+anti+human+jak2/Phospho-Jak+Family+(Tyr1007%2F1008)+Rabbit+mAb/pmc11177424-36-5-20
    Average 94 stars, based on 1 article reviews
    rabbit anti human phospho jak2 antibody - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc rabbit anti human p jak2
    ( A – D ) ISH was done with Mef2 intronic probes under each pharmacological inhibitor treatment; DMSO ( A ), 3i ( B ), Ruxolitinib ( C ) and 3i+Ruxolitinib ( D ). White arrows show the dotted signals of nascent Mef2 expression. White arrowhead shows lobe in ( B ). ( A ’– D ’) Magnification images of ( A – D ). ( A ”– D ”) Black and white images of the magenta channel of ( A’ – D’ ), respectively. ( E ) Proportion of B7.6* cells with Mef2 signals in nuclei ( y axis) under each pharmacological inhibitor treatment ( x axis). ( F ) Proportion of B7.6* lineage cells in embryos ( y axis) under each pharmacological inhibitor treatment. ( x axis). ( G – J ) Immunostaining with <t>anti-JAK2</t> antibody was done at the mid tailbud; 10 hpf ( G – H ’) and the late tailbud; 12 hpf ( I – J ’) stages. Image G is the same as the image on S5B. ( K ) Proportion of embryos with JAK2-positive B7.6* cells ( y axis). ( L , M ) ISH was done with Mef2 intronic probes under each pharmacological inhibitor treatment; DMSO ( L ) and Ruxolitinib ( M ) in 10 hpf embryos and quantified in ( N ). White arrows show the dotted signals of nascent Mef2 expression. ( N ) Proportion of Mef2 -positive B7.6* nuclei showing either 1 or 2 dots ( y axis) under each condition. ( O ) Proportion of cell numbers of B7.6* cells in embryos ( y axis) under each condition. Data information: ( E , F , K , N , O ) Error bars indicate standard error. P value was calculated by z-test. P > 0.05; N.S, 0.05> P > 0.01; *, 0.01> P ; **. Scale bars are 15 μm on ( A – D ), 20 μm on ( G , I ) and 5 μm on ( H , J , L , M ). .
    Rabbit Anti Human P Jak2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+anti+human+jak2/Phospho-Jak2+(Tyr1007)+Rabbit+mAb/ppr0835000-91-57-61
    Average 95 stars, based on 1 article reviews
    rabbit anti human p jak2 - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc rabbit anti human jak2
    ( A – D ) ISH was done with Mef2 intronic probes under each pharmacological inhibitor treatment; DMSO ( A ), 3i ( B ), Ruxolitinib ( C ) and 3i+Ruxolitinib ( D ). White arrows show the dotted signals of nascent Mef2 expression. White arrowhead shows lobe in ( B ). ( A ’– D ’) Magnification images of ( A – D ). ( A ”– D ”) Black and white images of the magenta channel of ( A’ – D’ ), respectively. ( E ) Proportion of B7.6* cells with Mef2 signals in nuclei ( y axis) under each pharmacological inhibitor treatment ( x axis). ( F ) Proportion of B7.6* lineage cells in embryos ( y axis) under each pharmacological inhibitor treatment. ( x axis). ( G – J ) Immunostaining with <t>anti-JAK2</t> antibody was done at the mid tailbud; 10 hpf ( G – H ’) and the late tailbud; 12 hpf ( I – J ’) stages. Image G is the same as the image on S5B. ( K ) Proportion of embryos with JAK2-positive B7.6* cells ( y axis). ( L , M ) ISH was done with Mef2 intronic probes under each pharmacological inhibitor treatment; DMSO ( L ) and Ruxolitinib ( M ) in 10 hpf embryos and quantified in ( N ). White arrows show the dotted signals of nascent Mef2 expression. ( N ) Proportion of Mef2 -positive B7.6* nuclei showing either 1 or 2 dots ( y axis) under each condition. ( O ) Proportion of cell numbers of B7.6* cells in embryos ( y axis) under each condition. Data information: ( E , F , K , N , O ) Error bars indicate standard error. P value was calculated by z-test. P > 0.05; N.S, 0.05> P > 0.01; *, 0.01> P ; **. Scale bars are 15 μm on ( A – D ), 20 μm on ( G , I ) and 5 μm on ( H , J , L , M ). .
    Rabbit Anti Human Jak2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+anti+human+jak2/Jak2+XP+Rabbit+mAb/ppr0835000-91-50-53
    Average 96 stars, based on 1 article reviews
    rabbit anti human jak2 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc rabbit anti human pjak2
    Pacritinib inhibits activities of JAK2, STAT3 and NF-κB. Protein extracts of JSC-1 and BCBL-1 cells treated for 48 h with 1 μM pacritinib (CTI BioPharma Corp.) or DMSO control were analyzed for the total and phosphorylated JAK2, STAT3 and p65 of NF-κB by Western blot. ( A ) JAK2, STAT3 and p65 indicate the total amount of the protein; <t>pJAK2,</t> pSTAT3 and p65 indicate the phosphorylated forms of the proteins, and β-actin serves as the internal control. Intensity of each band in JSC-1 group. Western blots were stripped after the initial probe of the phosphorylated proteins and β-actin and then probed with antibodies to the unphosphorylated proteins. The full scanned Western blots of Fig. 3A are provided in Supplemental File 12. ( B ) Signal intensities for JSC-1 and ( C ) BCBL-1 cells were normalized according to β-actin, and signal of all total and phosphorylated JAK2, STAT3 and p65 of NF-κB in the Pac-treated cells were presented as percentages compared with that of the control cells.
    Rabbit Anti Human Pjak2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+anti+human+jak2/Phospho-Jak2+(Tyr1007%2F1008)+Antibody/pmc10876599-233-16-19
    Average 96 stars, based on 1 article reviews
    rabbit anti human pjak2 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    Image Search Results


    ( A – D ) ISH was done with Mef2 intronic probes under each pharmacological inhibitor treatment; DMSO ( A ), 3i ( B ), Ruxolitinib ( C ) and 3i+Ruxolitinib ( D ). White arrows show the dotted signals of nascent Mef2 expression. White arrowhead shows lobe in ( B ). ( A ’– D ’) Magnification images of ( A – D ). ( A ”– D ”) Black and white images of the magenta channel of ( A’ – D’ ), respectively. ( E ) Proportion of B7.6* cells with Mef2 signals in nuclei ( y axis) under each pharmacological inhibitor treatment ( x axis). ( F ) Proportion of B7.6* lineage cells in embryos ( y axis) under each pharmacological inhibitor treatment. ( x axis). ( G – J ) Immunostaining with anti-JAK2 antibody was done at the mid tailbud; 10 hpf ( G – H ’) and the late tailbud; 12 hpf ( I – J ’) stages. Image G is the same as the image on S5B. ( K ) Proportion of embryos with JAK2-positive B7.6* cells ( y axis). ( L , M ) ISH was done with Mef2 intronic probes under each pharmacological inhibitor treatment; DMSO ( L ) and Ruxolitinib ( M ) in 10 hpf embryos and quantified in ( N ). White arrows show the dotted signals of nascent Mef2 expression. ( N ) Proportion of Mef2 -positive B7.6* nuclei showing either 1 or 2 dots ( y axis) under each condition. ( O ) Proportion of cell numbers of B7.6* cells in embryos ( y axis) under each condition. Data information: ( E , F , K , N , O ) Error bars indicate standard error. P value was calculated by z-test. P > 0.05; N.S, 0.05> P > 0.01; *, 0.01> P ; **. Scale bars are 15 μm on ( A – D ), 20 μm on ( G , I ) and 5 μm on ( H , J , L , M ). .

    Journal: EMBO Reports

    Article Title: Cellular remodeling and JAK inhibition promote zygotic gene expression in the Ciona germline

    doi: 10.1038/s44319-024-00139-0

    Figure Lengend Snippet: ( A – D ) ISH was done with Mef2 intronic probes under each pharmacological inhibitor treatment; DMSO ( A ), 3i ( B ), Ruxolitinib ( C ) and 3i+Ruxolitinib ( D ). White arrows show the dotted signals of nascent Mef2 expression. White arrowhead shows lobe in ( B ). ( A ’– D ’) Magnification images of ( A – D ). ( A ”– D ”) Black and white images of the magenta channel of ( A’ – D’ ), respectively. ( E ) Proportion of B7.6* cells with Mef2 signals in nuclei ( y axis) under each pharmacological inhibitor treatment ( x axis). ( F ) Proportion of B7.6* lineage cells in embryos ( y axis) under each pharmacological inhibitor treatment. ( x axis). ( G – J ) Immunostaining with anti-JAK2 antibody was done at the mid tailbud; 10 hpf ( G – H ’) and the late tailbud; 12 hpf ( I – J ’) stages. Image G is the same as the image on S5B. ( K ) Proportion of embryos with JAK2-positive B7.6* cells ( y axis). ( L , M ) ISH was done with Mef2 intronic probes under each pharmacological inhibitor treatment; DMSO ( L ) and Ruxolitinib ( M ) in 10 hpf embryos and quantified in ( N ). White arrows show the dotted signals of nascent Mef2 expression. ( N ) Proportion of Mef2 -positive B7.6* nuclei showing either 1 or 2 dots ( y axis) under each condition. ( O ) Proportion of cell numbers of B7.6* cells in embryos ( y axis) under each condition. Data information: ( E , F , K , N , O ) Error bars indicate standard error. P value was calculated by z-test. P > 0.05; N.S, 0.05> P > 0.01; *, 0.01> P ; **. Scale bars are 15 μm on ( A – D ), 20 μm on ( G , I ) and 5 μm on ( H , J , L , M ). .

    Article Snippet: A rabbit anti-human phospho-JAK2 (Y931) antibody (Thermo Fisher Scientific, PA5-104704) was used as a primary antibody, 1/500 in Can Get Signal Immunostain Solution A (TOYOBO).

    Techniques: Expressing, Immunostaining

    Pacritinib inhibits activities of JAK2, STAT3 and NF-κB. Protein extracts of JSC-1 and BCBL-1 cells treated for 48 h with 1 μM pacritinib (CTI BioPharma Corp.) or DMSO control were analyzed for the total and phosphorylated JAK2, STAT3 and p65 of NF-κB by Western blot. ( A ) JAK2, STAT3 and p65 indicate the total amount of the protein; pJAK2, pSTAT3 and p65 indicate the phosphorylated forms of the proteins, and β-actin serves as the internal control. Intensity of each band in JSC-1 group. Western blots were stripped after the initial probe of the phosphorylated proteins and β-actin and then probed with antibodies to the unphosphorylated proteins. The full scanned Western blots of Fig. 3A are provided in Supplemental File 12. ( B ) Signal intensities for JSC-1 and ( C ) BCBL-1 cells were normalized according to β-actin, and signal of all total and phosphorylated JAK2, STAT3 and p65 of NF-κB in the Pac-treated cells were presented as percentages compared with that of the control cells.

    Journal: Scientific Reports

    Article Title: Pacritinib inhibits proliferation of primary effusion lymphoma cells and production of viral interleukin-6 induced cytokines

    doi: 10.1038/s41598-024-54453-7

    Figure Lengend Snippet: Pacritinib inhibits activities of JAK2, STAT3 and NF-κB. Protein extracts of JSC-1 and BCBL-1 cells treated for 48 h with 1 μM pacritinib (CTI BioPharma Corp.) or DMSO control were analyzed for the total and phosphorylated JAK2, STAT3 and p65 of NF-κB by Western blot. ( A ) JAK2, STAT3 and p65 indicate the total amount of the protein; pJAK2, pSTAT3 and p65 indicate the phosphorylated forms of the proteins, and β-actin serves as the internal control. Intensity of each band in JSC-1 group. Western blots were stripped after the initial probe of the phosphorylated proteins and β-actin and then probed with antibodies to the unphosphorylated proteins. The full scanned Western blots of Fig. 3A are provided in Supplemental File 12. ( B ) Signal intensities for JSC-1 and ( C ) BCBL-1 cells were normalized according to β-actin, and signal of all total and phosphorylated JAK2, STAT3 and p65 of NF-κB in the Pac-treated cells were presented as percentages compared with that of the control cells.

    Article Snippet: Primary antibodies used were: mouse anti-β-actin (Sigma, cat# A2228), rabbit anti-human JAK2 (Cell Signaling, cat# 3230S), rabbit anti-human pJAK2 (Cell Signaling, cat# 3771S), rabbit anti-human STAT3 (Cell Signaling, cat# 12640S), rabbit anti-human pSTAT3 (Cell Signaling, cat# 9145S), rabbit anti-human p65 (Cell Signaling, cat# 8242S), mouse anti-human pp65 (Cell Signaling, cat# 3043S), and rabbit anti-human FLT3 (Cell Signaling, cat# 3462S), rabbit anti-human pFLT3 (Cell Signaling, cat# 3463S).

    Techniques: Control, Western Blot